PAN Foundation Launches Funds to Assist Homozygous Familial Hypercholesterolemia Patients
Washington, D.C., January 31, 2013 – Patient Access Network (PAN) Foundation is pleased to announce the launch of new disease funds designed to assist underinsured patients with inherited cholesterol disorder, homozygous familial hypercholesterolemia (HoFH). Patients of this rare but serious condition will now have greater access to life-saving medications because of PAN’s premium and co-pay assistance funds.
“PAN is dedicated to providing assistance to patients who need it the most,” explained Patrick McKercher, PAN President. “HoFH patients who qualify for PAN assistance will no longer face the burden of high out-of-pocket costs for their specialty medications or high premiums for their insurance coverage, giving them the ability to focus on what matters the most – their health,” Dr. McKercher continued.
PAN’s HoFH co-pay assistance fund allows patients to receive $10,000 per year to help cover the out-of-pocket costs associated with their specialty medications. Patients must be insured and their insurance must cover the medication for which they are seeking assistance. This fund is open to patients who are residing and receiving treatment in the U.S. and whose household gross income is at or below 500% FPL.
PAN’s HoFH Premium Assistance fund will provide assistance for the patient’s portion of the insurance premium associated with their coverage. This may involve an individual or family plan for those HoFH patients approved for assistance. Patients approved for the fund can either make the payments and be reimbursed by PAN or, depending on the employer and or payor situation, PAN can make the premium payments directly to the payor. This will be assessed and payment processes will be established as part of the approval process.
About Homozygous Familial Hypercholesterolemia
Familial hypercholesterolemia (abbreviated FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL, "bad cholesterol"), in the blood and early cardiovascular disease. Many patients have mutations in the LDLR gene that encodes the LDL receptor protein, which normally removes LDL from the circulation, or apolipoprotein B (ApoB), which is the part of LDL that binds with the receptor; mutations in other genes are rare. Patients who have one abnormal copy (are heterozygous) of the LDLR gene may have premature cardiovascular disease at the age of 30 to 40. Having two abnormal copies (being homozygous) may cause severe cardiovascular disease in childhood. Heterozygous FH is a common genetic disorder, inherited in an autosomal dominant pattern, occurring in 1:500 people in most countries; homozygous FH is much rarer, occurring in 1 in a million births. Homozygous FH often does not respond to medical therapy and may require other treatments, including LDL apheresis (removal of LDL in a method similar to dialysis) and occasionally liver transplantation.
About PAN Foundation
Patient Access Network (PAN) Foundation is an independent, national 501c3 organization dedicated to providing underinsured patients much needed financial assistance to cover out-of-pocket expenses related to qualifying treatments. PAN provides grants of $500 to $10,000 per year to qualified patients to help pay for medications for more than 40 cancers, chronic illnesses and rare diseases. Since 2004, PAN has provided more hundreds of millions of dollars in assistance for out-of-pocket expenses to hundreds of thousands of patients in need. For more information, visit www.PANfoundation.org.